<DOC>
	<DOCNO>NCT00230217</DOCNO>
	<brief_summary>This open-label , multi-center study 2 arm . The primary objective ass response treatment rasburicase 2 population adult pediatric patient lymphoma/leukemia/solid tumor malignancy , previously treat uricolytic agent , previously treat uricolytic agent first relapse refractory disease .</brief_summary>
	<brief_title>Study Rasburicase Treatment Prevention Hyperuricemia Associated With Tumor Lysis Syndrome Patients With Relapsed Refractory Lymphoma , Leukemia , Solid Tumor Malignancy</brief_title>
	<detailed_description>This multi-center , 2 arm , open-label study ; - Arm A : Patients previously treat uricolytic agent ; - Arm B : Patients previously treat uricolytic agent . Patients receive rasburicase 5 day begin chemotherapy 4-24 hour first dose rasburicase . Patients follow 14 35 day , 3 6 month every 6 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>1 . Meets one follow risk criterion tumor lysis syndrome ( TLS ) : A patient high risk TLS he/she present : Hyperuricemia malignancy ( plasma uric acid &gt; 7.5 mg/dL ) ; A diagnosis aggressive lymphoma/leukemia base Revised EuropeanAmerican Lymphoma ( REAL ) classification lymphoma/leukemia ; Acute myeloid leukemia ( AML ) ; Chronic myeloid leukemia ( CML ) blast crisis ; High grade myelodysplastic syndrome ( refractory anemia excess blast , refractory anemia excess blast transformation , chronic myelomonocytic leukemia ) &gt; 10 % bone marrow blast give aggressive treatment similar AML A patient potential risk TLS he/she present : A diagnosis aggressive lymphoma/leukemia base REAL classification lymphoma/leukemia plus 1 follow criterion : Lactate dehydrogenase ( LDH ) &gt; 2 x upper limit normal ( ULN ) ( IU/L ) Stage IIIIV disease Stage III disease 1 lymph node/tumor &gt; 5 cm diameter 2 . Patients previously treat uricolytic agent first relapse refractory disease 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 03 . ECOG equivalent derive Karnofsky performance scale 10030 Lansky performance score 10030 ( patient &lt; = 16 year age ) may also use . 4 . Life expectancy &gt; 3 month 5 . Negative pregnancy test ( female child bear potential ) use effective contraceptive method ( male female ) . A pregnancy test may perform serum urine human chorionic gonadotropin ( HCG ) . 6 . Signed write informed consent 1 . History establish diagnosis asthma severe lifethreatening atopic allergy 2 . Hypersensitivity uricases excipients 3 . Known history glucose6phosphate dehydrogenase ( G6PD ) deficiency history hemolysis indicative G6PD deficiency 4 . Pregnant lactate 5 . Concomitant treatment investigational drug 6 . Planned treatment rituximab 7 . Receipt rituximab within 12 month period prior study entry 8 . Unwilling unable comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Refracturing</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>